Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transpl - Wikidata - wikimedia - TriplyDB

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transpl

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transpl

http://www.wikidata.org/entity/Q37609957

about

The European Hematology Association Roadmap for European Hematology Research: a consensus document Late effects of blood and marrow transplantation.Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.Hypomethylating agents after allogeneic blood stem cell transplantation.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.Lymphocyte recovery is an independent predictor of relapse in allogeneic hematopoietic cell transplantation recipients for acute leukemia.Haplo, we have a problem.Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation.Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation.First-in-human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse after Transplantation.Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation.Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome.Relapse post hematopoietic SCT remains the Achilles heel for the field.Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working pa

P2860

Q28830861-FD4C93C4-77AE-4829-B66E-78BD9962C7DC Q33574136-ABA9E6C7-2561-46EC-8C40-B54016F559C5 Q33831349-72358F61-8165-46B5-9054-48D17BDE1257 Q34380489-DE49D3C6-DAD1-4497-8799-8A4EF6E31B7B Q36055095-9DED4525-F51D-4DB8-A61D-737F171550DC Q37531039-95887701-0BD4-416E-BE8C-445FDF3AEB74 Q37579561-9231C541-D273-4970-AEF9-74FE9F2A2F85 Q37624593-A400FAB1-D40A-43B8-80A1-12702B1D2628 Q38199056-71F621B4-ADDF-4E83-BFB7-51F751954C29 Q38654516-D1E3F1B1-D1E4-468B-A53C-511CB7F8F5A0 Q38863489-A26BF7C7-E922-4BE8-8ACB-CC1742831CB3 Q39106490-BF23F33D-68E4-4F6D-B899-1755C0CF45BF Q40313702-3BBF040C-5990-4636-AE6F-5B396DDF4C1F Q40454294-26CF050A-455E-4E13-A306-02F800C2DD06 Q40519376-2A2BE743-C0DE-446E-B159-10249DF9F6CB Q40639927-672EC296-207F-416F-9511-3A40BABF39FF Q41539854-8EA6DC47-2909-4D33-AE1B-95E86B662F02 Q42101234-C2139143-F304-4ACA-AA22-CE1B3AFA21EA Q46263769-E9815F50-13D9-4C66-B7CF-20B15FD1A742 Q48273861-FC18B734-3E98-434F-8E6E-1D3342B08565 Q48339189-BC0F9C7F-3578-4986-94B8-5B38626C5E6B Q49791810-BDFA52E4-BEE0-4B65-8CEE-3A0F2194A8CF Q49905502-F477E06A-7134-4DF5-8004-B7CA43FACBFF Q49976405-21CF2217-A652-4719-BC43-3157DD4622B1 Q50687630-1EC5C1E2-E3E0-4EAB-B763-40326081610F Q52870483-FD89B1B1-2431-41A5-A370-CB6336E3505F Q53029398-FBC26529-69D3-4000-81FC-5A1334B05FD0 Q53776386-6DD4B753-8E9A-4795-BABE-67A7B2EA5DFC Q55073539-B511A139-8CA1-45DE-A784-05B7BF5DEE64

P2860

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transpl

http://www.wikidata.org/entity/Q37609957

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Proceedings from the National ...... lapse after allogeneic transpl

@en

Proceedings from the National ...... lapse after allogeneic transpl

@nl

type

label

Proceedings from the National ...... lapse after allogeneic transpl

@en

Proceedings from the National ...... lapse after allogeneic transpl

@nl

prefLabel

Proceedings from the National ...... lapse after allogeneic transpl

@en

Proceedings from the National ...... lapse after allogeneic transpl

@nl

P1433

Q37609957-5F566E28-7CAC-467F-A810-6ADF9A4BD5E8

P1476

Q37609957-E97AC52B-2AE2-480F-9A3A-B6C4724ADC6C

P2093

Q37609957-0F08E929-CBDA-4385-A293-19131FA18729

Q37609957-3BF931BD-94CA-4551-A78A-6B9604377251

Q37609957-443729CD-8A7B-4D4D-8A92-8E50C3DFEEAB

Q37609957-5CC03B1B-F3A0-480A-9336-6EBA461A5282

Q37609957-9710FDFC-7548-4885-A223-FCC29DAB36AF

Q37609957-9AC2633F-AA35-4628-B325-4730A1D8832E

Q37609957-BB93D337-1302-45BF-A765-4A52107F05F0

Q37609957-C6F80BBC-1067-436D-B3F1-97F566A632EC

Q37609957-F337EEAC-2FE3-43D3-AF79-C308DD56BE9C

P2860

Q37609957-00020374-FC5C-43BC-94E1-C608472F615A

Q37609957-00CE7EB5-34E2-4DA0-855A-0CD0EF2E3DE0

Q37609957-18838FEA-F8F1-4257-821B-A88DADA620B1

Q37609957-2236626D-76C6-4EC3-8BA3-5CF9FB47BFA9

Q37609957-27316487-B09A-4EBD-ADE8-62ED74B6F80D

Q37609957-2E8A6E3A-0D0D-4A2A-A4D3-6129F388BA46

Q37609957-2F2E2853-6DD1-4A7F-A900-FF68F0EC64D7

Q37609957-304F0A09-E234-4F5A-A1B7-9DA8623EB547

Q37609957-36C5E186-8AA7-4EAD-B123-C74CEC367DE7

Q37609957-387E1D14-39AD-4CCF-BD4F-1E24DA5A73D0

P304

Q37609957-2E27F9B3-A8A1-46D7-9CE7-B5C7AE4F10F5

P31

Q37609957-FEC4643C-BAB2-4FE6-BCF2-72D8336939CA

P356

Q37609957-300EA441-A0AF-4D9E-A267-E4588FE4B036

P433

Q37609957-CB951E19-DA25-4D72-9640-56A1A8D3C10E

P478

Q37609957-657C883A-8B1D-4287-9F50-B3A95D997FE6

P577

Q37609957-4BF71CC1-0CB9-452D-97CC-54F0309E851F

P5875

Q37609957-15F9070A-193B-4CD5-8156-232AA300A7AD

P698

Q37609957-240A6566-F4FE-47E6-9699-6B8052D7AA4C

P921

Q37609957-3E1CD97E-B2E7-4AF1-8E56-3624249C432F

P932

Q37609957-400141F3-7A7C-4F7A-B7B2-5775B3256823

P356

J.BBMT.2013.08.012

P1433

Biology of Blood and Marrow Transplantation

P1476

Proceedings from the National ...... lapse after allogeneic transpl

@en

P2093

Alan S Wayne

http://www.w3.org/2001/XMLSchema#string

Christoph Schmid

http://www.w3.org/2001/XMLSchema#string

David L Porter

http://www.w3.org/2001/XMLSchema#string

Marcos de Lima

http://www.w3.org/2001/XMLSchema#string

Michael R Bishop

http://www.w3.org/2001/XMLSchema#string

Minoo Battiwalla

http://www.w3.org/2001/XMLSchema#string

Nancy M Hardy

http://www.w3.org/2001/XMLSchema#string

Nicolaus Kröger

http://www.w3.org/2001/XMLSchema#string

Sergio A Giralt

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Novel human interleukin-15 agonists

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.

P304

4-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2013.08.012

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256480730

http://www.w3.org/2001/XMLSchema#string

P698

24018392

http://www.w3.org/2001/XMLSchema#string

P921

P932

3938421

http://www.w3.org/2001/XMLSchema#string